Can Geodon (ziprasidone) cause extrapyramidal symptoms (EPS)?

Yes, Geodon (ziprasidone) can cause extrapyramidal symptoms (EPS), though the risk is lower compared to conventional antipsychotics.

Ziprasidone is associated with EPS including dystonia, akathisia, and parkinsonism, but notably demonstrates less movement disorder risk than many other antipsychotics, particularly risperidone. 1

Evidence from FDA Labeling

The FDA-approved drug label explicitly warns that ziprasidone may cause extrapyramidal symptoms including tremors and abnormal muscle movements, particularly in neonates exposed in utero and in breastfeeding infants 2. The label advises monitoring for these symptoms and seeking medical care if they occur.

Clinical Evidence on EPS Risk

Comparative Risk Profile

Ziprasidone shows a favorable EPS profile compared to conventional antipsychotics and some other atypical agents:

• In emergency department studies, ziprasidone 20 mg IM demonstrated "absence of movement disorders, including extrapyramidal symptoms, dystonia, and hypertonia" which was described as "noteworthy" 1

• When compared head-to-head with haloperidol, ziprasidone was "better tolerated, particularly in the incidence of movement disorders" 1

• A systematic meta-analysis of SGAs found that ziprasidone required significantly less antiparkinson medication than risperidone, though more than olanzapine and quetiapine 3

Documented EPS Cases

Despite the lower risk, EPS can and does occur with ziprasidone:

• Acute dystonia has been reported, including at standard doses (80 mg/day) 4 and particularly at high doses (240 mg/day) 5

• Akathisia occurs with ziprasidone, with risk differences of 2.3% in bipolar depression (NNTH=44) and 8.4% in bipolar mania (NNTH=12) compared to placebo 6

• Overall EPS showed risk differences of 8.7% in bipolar mania (NNTH=12) and 3.3% in schizophrenia (NNTH=30) versus placebo 6

• Tardive dyskinesia has been documented after 23-34 months of ziprasidone monotherapy 7, and even rare tardive laryngeal dystonia after 8 months at 120 mg/day 8

Dose-Dependent Considerations

EPS risk appears dose-related:

• No EPS at 160 mg/day but marked acute dystonia at 240 mg/day in one documented case 5
• Patients with bipolar mania appear more vulnerable to EPS than those with bipolar depression or schizophrenia 6

Clinical Management Algorithm

When prescribing ziprasidone:

1. Baseline assessment: Document any pre-existing movement disorders using standardized scales (e.g., Abnormal Involuntary Movement Scale)

2. Risk stratification: Young males are at higher risk for acute dystonia 9; patients with bipolar mania have higher EPS vulnerability 6

3. Monitoring schedule:

   • Assess for EPS at each visit during dose titration
   • Screen for tardive dyskinesia every 3-6 months during maintenance 9
   • Monitor specifically for akathisia (often misinterpreted as psychotic agitation) 9

4. Treatment of EPS if it occurs:

   • Acute dystonia: Anticholinergic or antihistaminic medications provide rapid relief 9
   • Akathisia: Reduce dose if feasible; consider β-blockers or benzodiazepines (antiparkinsonian agents often ineffective) 9
   • Parkinsonism: Add anticholinergic agent or amantadine, or reduce dose 9

Important Caveats

• Children and adolescents may be at higher risk for EPS than adults 9
• The absence of EPS at therapeutic doses does not guarantee safety at higher doses 5
• While ziprasidone has advantages over conventional antipsychotics and risperidone, it still carries meaningful EPS risk that requires monitoring 6, 3
• Patients should be counseled about EPS symptoms and instructed to report restlessness, muscle stiffness, or involuntary movements immediately 2